التفاصيل البيبلوغرافية
| العنوان: |
POS1325 COMPARISON OF THREE DIFFERENT ALGORITHMS FOR THE TREATMENT OF CHILDREN WITH POLYARTICULAR JIA: THE FIRST YEAR AFTER DIAGNOSIS |
| المؤلفون: |
Minden, K., Schwarz, T., Dressler, F., Foeldvari, I., Haas, J. P., Horneff, G., Hospach, T., Kümmerle-Deschner, J., Moenkemoeller, K., Weller-Heinemann, F., Tenbrock, K., Niewerth, M., Sengler, C., Foell, D., Klotsche, J. |
| المصدر: |
Annals of the Rheumatic Diseases ; volume 80, issue Suppl 1, page 945.1-945 ; ISSN 0003-4967 1468-2060 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
General Biochemistry, Genetics and Molecular Biology, Immunology, Immunology and Allergy, Rheumatology |
| الوصف: |
Background: Various treatment strategies are used for children with newly diagnosed polyarticular JIA. MTX is usually prescribed, sometimes in combination with high-dose intravenous glucocorticoid pulses (HDGC) or multiple intra-articular GC injections (IAGC). These different approaches were considered in the German consensus-based treatment protocols for polyarticular JIA 1 , they were also the leading therapies in patients with rheumatoid factor-negative polyarthritis (RF- PA) included in the JIA inception cohort ICON. Objectives: To compare the effectiveness of three different treatment strategies in nearly DMARD-naïve patients with RF- PA. Methods: Patients with RF- PA who were included in the ICON cohort and received one of the following treatments within the first three months were considered for the analysis: Group 1: MTX + IAGC in >4 joints, Group 2: MTX + HDGC, Group 3: MTX, no IAGC in >4 joints, no HDGC. Propensity score-adjusted group differences in outcomes after one and two years were analysed by linear and logistic regression analyses. Results: The analysis included data from 150 patients (79% female, mean age 6.7±4.8 years) enrolled in ICON 1.6±1.9 months after the diagnosis of RF- PA, of whom 52 were in Group 1, 54 in Group 2 and 44 in Group 3. Disease activity did not differ significantly between the groups at treatment start (cJADAS-10 16.7±4.7, 15.8±5.7, 15.9±6.5, respectively). Of the total group, at 1- and 2-year follow-up (FU), 60.9%/60.1% and 52.3%/58.8% of patients had inactive disease (cJADAS ≤1/Wallace criteria 2 ), 21.3% and 35.6% were in remission off drug 2 , and mean cJADAS-10 scores were 2.6±3.9 and 3.0±3.5, respectively. 60.5% and 67.0% had no functional limitations (CHAQ=0). Patients in Group 1 more often had an inactive disease (according to Wallace 2 ) at the 1-year FU and tended to have inactive disease more often at 2-year FU than patients in Group 3 (78.1% vs. 45.2%, p=0.025; 73.3 vs. 49.1%, p=0.075, respectively). Group 2 patients (inactive disease in 56.1% and 53.4% ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/annrheumdis-2021-eular.3448 |
| الإتاحة: |
https://doi.org/10.1136/annrheumdis-2021-eular.3448Test |
| رقم الانضمام: |
edsbas.CBE39237 |
| قاعدة البيانات: |
BASE |
